GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlaxoSmithKline (GSK) is conducting a study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a.’ The primary objective is to assess the safety and tolerability of salbutamol in adults with asthma, using two different propellants in inhalers. This study is significant as it could lead to improved asthma treatments with better safety profiles.
The study tests two interventions: Salbutamol HFA-152a and Salbutamol HFA-134a, both delivered via metered dose inhalers. These drugs aim to provide effective asthma relief while evaluating the safety of the new propellant, HFA-152a, compared to the traditional HFA-134a.
This is an interventional, Phase 3 study with a randomized, parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of the study is treatment-focused.
The study began on May 31, 2024, with an estimated completion date yet to be announced. The last update was submitted on July 2, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could impact GSK’s stock performance positively if the new propellant demonstrates superior safety and efficacy, potentially setting a new standard in asthma treatment. This could also influence investor sentiment and position GSK favorably against competitors in the respiratory treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.